Concordia International (CXR) Stock Price Down 2.4%

Concordia International Corp (TSE:CXR) (NASDAQ:CXRX) was down 2.4% during mid-day trading on Thursday . The company traded as low as C$0.77 and last traded at C$0.80. Approximately 81,286 shares changed hands during trading, a decline of 57% from the average daily volume of 188,021 shares. The stock had previously closed at C$0.82.

The stock has a market capitalization of $40.63, a PE ratio of -0.02 and a beta of -1.65.

Concordia International (TSE:CXR) (NASDAQ:CXRX) last posted its quarterly earnings results on Tuesday, November 14th. The company reported C$0.08 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of C$0.17 by C($0.09).

COPYRIGHT VIOLATION NOTICE: “Concordia International (CXR) Stock Price Down 2.4%” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/02/10/concordia-international-cxr-stock-price-down-2-4.html.

About Concordia International

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Receive News & Ratings for Concordia International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit